Canopy Growth's Turnaround Narrative Gains Traction, Even as the Share Price Plays Hard to Get

Canopy Growth posts 13% revenue growth, narrows losses, and secures EU GMP renewal, but shares remain down over 12 months.

The disconnect between a company's operational reality and its stock market reception is rarely as stark as it is right now with Canopy Growth. The Canadian cannabis producer has spent the past several weeks quietly checking boxes — refinancing debt, closing acquisitions, securing European regulatory approvals — yet the share price remains stubbornly entrenched in negative territory on a 12-month basis.

At the heart of this tension sits a freshly published annual report for fiscal 2026 that paints a picture of a business genuinely committed to restructuring. The most significant development buried within those filings: Canopy Growth has completed a US$150 million senior secured term loan to replace its previous first-lien credit facility. For a company that has spent years wrestling with its capital structure, this cleaner balance-sheet architecture represents tangible progress — even if it failed to generate headlines.

The Numbers Tell a Story of Momentum

The operational evidence supporting this cautious optimism arrived on August 7, when Canopy Growth reported first-quarter results for fiscal 2027. Net revenue came in at C$81.2 million, a 13 percent year-over-year increase driven by growth across all business segments. The medical cannabis division in Canada proved particularly robust, with revenue climbing 22 percent, buoyed by the integration of MTL Cannabis — an acquisition that closed on March 16.

Perhaps more tellingly, the company's GAAP net loss narrowed by 68 percent to C$14.6 million. Media reports following the earnings release suggested both revenue and profit exceeded analyst expectations — a notable achievement for a company long associated with missed forecasts. The consensus estimate for the quarter ending in September sits at a loss of US$0.03 per share, which would represent a 200 percent decline from the prior-year period, though analysts have been adjusting their price targets upward since the results landed. By August 12, the average target had been revised to C$2.02, with the smaller-than-expected losses drawing positive commentary.

A Regulatory Seal for European Ambitions

While the earnings release captured most of the attention, a quieter but strategically important milestone came on August 14. The production facility in Kincardine, Ontario, received renewed EU Good Manufacturing Practice (GMP) certification from the Regierungspräsidium Tübingen in Germany. This designation is essential for maintaining access to European medical cannabis markets — a cornerstone of management's international growth strategy.

The timing is no coincidence. The company has already dispatched its fiscal 2026 annual report and proxy materials to shareholders ahead of the annual and special meeting scheduled for September 25. That gathering is expected to offer further clarity on the company's long-term strategic direction.

The Market Remains Unconvinced

Yet for all the operational progress, the stock chart tells a more cautious story. Shares currently trade at €0.9108, roughly 54 percent below the 52-week high of €2.00 reached in December. The stock has declined 13 percent since the start of the year and sits 29 percent lower over the past twelve months. The recent 30-day performance offers a modest bright spot — a 13 percent gain — and the relative strength index of 60.7 suggests the selling pressure has at least abated.

The technical picture shows the shares trading 8.5 percent above their 50-day moving average of €0.8393, indicating some stabilization. But the broader trend remains one of market skepticism, a sentiment reflected in the consensus rating of "Hold" from the eight analyst houses covering the stock. Their average recommendation scores 2.50 on a scale between "Hold" and "Buy," with a twelve-month consensus price target of US$1.72.

Institutional interest is nonetheless firming. Some 234 institutional investors now hold positions in the company, including Toroso Investments and the Amplify Alternative Harvest ETF. After years of dilutive capital raises, accounting issues, and disappointing guidance, however, rebuilding investor trust will require more than a single strong quarter.

The fundamental question hanging over Canopy Growth is whether the operational turnaround — cleaner debt, growing revenue, regulatory security — can eventually close the gap with a share price that has yet to reflect it. The September shareholder meeting may offer the next clue, but the market has made clear it needs sustained evidence before rewriting its verdict.